ID
29055
Descripción
Ropinirole Case Report Form GSK RRL100013 GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage
Palabras clave
Versiones (5)
- 5/10/17 5/10/17 -
- 22/2/18 22/2/18 -
- 22/2/18 22/2/18 -
- 22/2/18 22/2/18 -
- 17/9/21 17/9/21 -
Titular de derechos de autor
gsk
Subido en
22 de febrero de 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Ropinirole Case Report Form GSK RRL100013
STATUS OF TREATMENT BLIND
Descripción
PGx-PHARMACOGENETIC RESEARCH INSTRUCTIONS
Descripción
The question "Has informed consent been obtained for PGx-Pharmacogenetic research?" should be completed at the beginning of the study. If the question is answered No, I/ one box for reason and do not complete the remainder of the page. WITHDRAWAL OF CONSENT The question "Has the subject withdrawn consent for PGx-Pharmacogenetic research?" must be completed immediately if the subject withdraws consent. Otherwise, it must be completed when the subject leaves the study. It must be completed for all subjects for whom informed consent was obtained for PGx-Pharmacogenetic research. If consent is withdrawn, a request for destruction must be made and Blood Sample Destruction section below completed. BLOOD SAMPLE DESTRUCT/ON Do not complete this section if a blood sample was not collected. The question "Has a request been made for sample destruction?" must be completed immediately if there is a request for sample destruction. Otherwise, it must be completed when the subject leaves the study. It must be completed for all subjects for whom a blood sample was obtained for PGx-Pharmacogenetic research. If the question is answered Yes, I/one box for reason.
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0031325
- UMLS CUI [1,2]
- C1442085
Descripción
PGx-PHARMACOGENETIC RESEARCH
Descripción
CONSENT FOR PGx-PHARMACOGENETIC RESEARCH
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021430
- UMLS CUI [1,2]
- C2347500
Descripción
Informed consent if yes
Tipo de datos
date
Alias
- UMLS CUI [1]
- C2985782
Descripción
Informed consent if no
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0021430
Descripción
BLOOD SAMPLE COLLECTION
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0005834
Descripción
If Yes, record the date sample taken
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C0005834
- UMLS CUI [1,2]
- C0011008
Descripción
WITHDRAWAL OF CONSENT
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1707492
Descripción
BLOOD SAMPLE DESTRUCTION
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
Descripción
If Yes: BLOOD SAMPLE DESTRUCTION
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C1948029
- UMLS CUI [1,2]
- C0178913
Descripción
The following lists of abbreviations are examples which can be used to aid the completion of the appropriate items on the Concomitant Medications page. These are not all inclusive lists and are for guidance only, other abbreviations not listed may be used if necessary.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C2347852
Descripción
UNITS
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1519795
Similar models
STATUS OF TREATMENT BLIND
C2347038 (UMLS CUI [1,2])
C2347038 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
C1442085 (UMLS CUI [1,2])
C2347500 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0178913 (UMLS CUI [1,2])
C0178913 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)